vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and Silvercrest Asset Management Group Inc. (SAMG). Click either name above to swap in a different company.
Silvercrest Asset Management Group Inc. is the larger business by last-quarter revenue ($32.0M vs $18.7M, roughly 1.7× CytomX Therapeutics, Inc.). Silvercrest Asset Management Group Inc. runs the higher net margin — -0.4% vs -0.8%, a 0.4% gap on every dollar of revenue. On growth, Silvercrest Asset Management Group Inc. posted the faster year-over-year revenue change (-0.0% vs -25.7%). Silvercrest Asset Management Group Inc. produced more free cash flow last quarter ($15.0M vs $-15.8M). Over the past eight quarters, Silvercrest Asset Management Group Inc.'s revenue compounded faster (2.7% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CTMX vs SAMG — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $32.0M |
| Net Profit | $-154.0K | $-120.0K |
| Gross Margin | — | — |
| Operating Margin | -6.9% | -2.8% |
| Net Margin | -0.8% | -0.4% |
| Revenue YoY | -25.7% | -0.0% |
| Net Profit YoY | 97.6% | -107.4% |
| EPS (diluted) | — | $0.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $32.0M | ||
| Q3 25 | — | $31.3M | ||
| Q2 25 | $18.7M | $30.7M | ||
| Q1 25 | $50.9M | $31.4M | ||
| Q4 24 | $38.1M | $32.0M | ||
| Q3 24 | $33.4M | $30.4M | ||
| Q2 24 | $25.1M | $31.0M | ||
| Q1 24 | $41.5M | $30.3M |
| Q4 25 | — | $-120.0K | ||
| Q3 25 | — | $618.0K | ||
| Q2 25 | $-154.0K | $1.9M | ||
| Q1 25 | $23.5M | $2.5M | ||
| Q4 24 | $18.9M | $1.6M | ||
| Q3 24 | $5.7M | $2.3M | ||
| Q2 24 | $-6.5M | $2.7M | ||
| Q1 24 | $13.8M | $3.0M |
| Q4 25 | — | -2.8% | ||
| Q3 25 | — | 4.3% | ||
| Q2 25 | -6.9% | 13.2% | ||
| Q1 25 | 44.4% | 15.4% | ||
| Q4 24 | 46.4% | 6.1% | ||
| Q3 24 | 12.3% | 14.6% | ||
| Q2 24 | -33.7% | 17.1% | ||
| Q1 24 | 28.1% | 19.5% |
| Q4 25 | — | -0.4% | ||
| Q3 25 | — | 2.0% | ||
| Q2 25 | -0.8% | 6.3% | ||
| Q1 25 | 46.2% | 7.9% | ||
| Q4 24 | 49.6% | 5.1% | ||
| Q3 24 | 17.2% | 7.4% | ||
| Q2 24 | -26.0% | 8.6% | ||
| Q1 24 | 33.3% | 9.9% |
| Q4 25 | — | $0.02 | ||
| Q3 25 | — | $0.07 | ||
| Q2 25 | — | $0.21 | ||
| Q1 25 | — | $0.26 | ||
| Q4 24 | — | $0.16 | ||
| Q3 24 | — | $0.24 | ||
| Q2 24 | — | $0.28 | ||
| Q1 24 | — | $0.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $44.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $50.3M |
| Total Assets | $175.1M | $166.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $44.1M | ||
| Q3 25 | — | $36.1M | ||
| Q2 25 | $49.0M | $30.0M | ||
| Q1 25 | $47.6M | $36.3M | ||
| Q4 24 | $38.1M | $68.6M | ||
| Q3 24 | $40.6M | $58.1M | ||
| Q2 24 | $43.2M | $49.9M | ||
| Q1 24 | $36.2M | $39.7M |
| Q4 25 | — | $50.3M | ||
| Q3 25 | — | $58.9M | ||
| Q2 25 | $119.9M | $64.6M | ||
| Q1 25 | $25.0M | $80.0M | ||
| Q4 24 | $-456.0K | $80.7M | ||
| Q3 24 | $-23.5M | $84.6M | ||
| Q2 24 | $-31.2M | $85.3M | ||
| Q1 24 | $-31.7M | $83.9M |
| Q4 25 | — | $166.6M | ||
| Q3 25 | — | $157.6M | ||
| Q2 25 | $175.1M | $152.7M | ||
| Q1 25 | $98.5M | $159.9M | ||
| Q4 24 | $120.5M | $194.4M | ||
| Q3 24 | $139.0M | $184.2M | ||
| Q2 24 | $159.2M | $177.6M | ||
| Q1 24 | $184.7M | $170.2M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $18.6M |
| Free Cash FlowOCF − Capex | $-15.8M | $15.0M |
| FCF MarginFCF / Revenue | -84.6% | 46.9% |
| Capex IntensityCapex / Revenue | 0.1% | 11.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $17.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $18.6M | ||
| Q3 25 | — | $14.6M | ||
| Q2 25 | $-15.8M | $13.8M | ||
| Q1 25 | $-21.0M | $-24.7M | ||
| Q4 24 | $-19.9M | $21.6M | ||
| Q3 24 | $-20.7M | $13.3M | ||
| Q2 24 | $-19.5M | $16.0M | ||
| Q1 24 | $-26.0M | $-24.1M |
| Q4 25 | — | $15.0M | ||
| Q3 25 | — | $13.8M | ||
| Q2 25 | $-15.8M | $13.4M | ||
| Q1 25 | $-21.2M | $-25.1M | ||
| Q4 24 | $-20.0M | $19.9M | ||
| Q3 24 | $-20.7M | $12.9M | ||
| Q2 24 | $-19.6M | $15.6M | ||
| Q1 24 | $-26.2M | $-24.7M |
| Q4 25 | — | 46.9% | ||
| Q3 25 | — | 44.1% | ||
| Q2 25 | -84.6% | 43.6% | ||
| Q1 25 | -41.6% | -80.0% | ||
| Q4 24 | -52.5% | 62.2% | ||
| Q3 24 | -62.1% | 42.4% | ||
| Q2 24 | -78.2% | 50.4% | ||
| Q1 24 | -63.1% | -81.6% |
| Q4 25 | — | 11.4% | ||
| Q3 25 | — | 2.6% | ||
| Q2 25 | 0.1% | 1.5% | ||
| Q1 25 | 0.2% | 1.3% | ||
| Q4 24 | 0.2% | 5.3% | ||
| Q3 24 | 0.1% | 1.2% | ||
| Q2 24 | 0.4% | 1.1% | ||
| Q1 24 | 0.3% | 2.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | 23.62× | ||
| Q2 25 | — | 7.22× | ||
| Q1 25 | -0.89× | -10.01× | ||
| Q4 24 | -1.05× | 13.34× | ||
| Q3 24 | -3.61× | 5.90× | ||
| Q2 24 | — | 6.00× | ||
| Q1 24 | -1.89× | -8.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
SAMG
| Investment Advisory Management And Administrative Service | $30.7M | 96% |
| Tax And Family Office Services | $1.2M | 4% |
